



## 2021 Virtual Congress – Scientific Program

All program timing in CEST

<b>Day 1, Friday, May 7<sup>th</sup></b>	
<b>11:45-13:15</b>	<b>B-cell maturation antigen (BCMA)-targeted agents: Emerging clinical considerations for a new pillar of therapy for the treatment of relapsed/refractory multiple myeloma (RRMM)</b> <i>Industry Symposium</i>
<b>13:15-13:30</b>	<b>Welcome by Congress chairs</b>
<b>13:30-15:00</b>	<b>Session 1: High risk disease biology</b>
13:30-13:45	Disease risk scoring <b>Hervé Avet-Loiseau, France</b>
13:45-14:00	Genomics of high-risk myeloma <b>Nikhil Munshi, USA</b>
14:00-14:15	IMiDs resistance pathways <b>Keith Stewart, Canada</b>
14:15-15:00	Round table debate <i>Speakers and,</i> <b>Gordon Cook, UK</b> <b>Gareth Morgan, USA</b>
<b>15:00-16:30</b>	<b>Session 2: Immune deregulation in myeloma</b>
15:00-15:15	Role of the microenvironment <b>Irene Ghobrial, USA</b>
15:15-15:30	Mechanisms of resistance to immunotherapy <b>Niels van de Donk, Netherlands</b>
15:30-15:45	Strategies to reverse immune deregulation in myeloma <b>Paola Neri, Canada</b>
15:45-16:30	Round table debate <i>Speakers and,</i> <b>Michael O’Dwyer, Ireland</b> <b>Bertrand Arnulf, France</b> <b>Marc Raab, Germany</b>
<b>16:30-18:00</b>	<b><i>Close combat: bringing the immune system in to defeat multiple myeloma</i></b> <i>Industry Symposium</i>
<b>18:00-19:15</b>	<b>Session 3: Plenary lectures</b>
18:00-18:25	Therapy of AL amyloidosis: an update <b>Giampaolo Merlini, Italy</b>
18:25-18:50	Therapy of Waldenstrom macroglobulinemia <b>Steve Treon, USA</b>
18:50-19:15	Round table debate <i>Speakers and,</i> <b>Jorge Castillo, USA</b>
<b>19:15-20:45</b>	<b><i>Should cure be the goal for multiple myeloma?</i></b> <i>Non-profit Symposium</i>



<b>Day 2, Saturday, May 8<sup>th</sup></b>	
<b>10:00-11:00</b>	<b>Session 4: Snapshot talks (part 1) - Latest data</b>
10:00-10:10	Latest data on HDAC inhibitors <b>Enrique Ocio</b> , Spain
10:10-10:20	Latest data on Targeting SLAMF7 <b>Katia Weisel</b> , Germany
10:20-10:30	Latest data on targeting Bcl2 inhibitors <b>Cyrille Touzeau</b> , France
10:30-10:45	New IMWG guidelines for the management of bone disease in myeloma <b>Evangelos Terpos</b> , Greece
10:45-10:55	Latest data on antibody drug conjugates <b>Suzan Trudel</b> , Canada
10:55-11:05	Latest data in extra-medullary disease <b>Artur Jurczyszyn</b> , Poland
<b>11:05-12:20</b>	<b>Session 5: Snapshot talks (part 2) - Clinical trials updates</b>
11:05-11:15	IFM 2009 <b>Aurore Perrot</b> , France
11:15-11:25	Carfilzomib, lenalidomide, and dexamethasone plus transplant <b>Andrzej Jakubowiak</b> , USA
11:25-11:35	GRIFFIN <b>Jonathan Kaufman</b> , USA
11:35-11:45	MASTER <b>Luciano Costa</b> , USA
11:45-11:55	IKEMA <b>Tom Martin</b> , USA
11:55-12:05	CANDOR <b>Saad Usmani</b> , USA
12:05-12:30	Q&A
<b>12:30-13:45</b>	<b><i>Cellular therapies: perspectives for practice Industry Symposium</i></b>
<b>13:45-15:00</b>	<b>Session 6: Therapy of young patients</b>
13:45-14:00	The optimal induction regimen <b>Philippe Moreau</b> , France
14:00-14:15	Role of consolidation (including double auto-transplant) <b>Michele Cavo</b> , Italy
14:15-14:30	Maintenance approaches post-transplant <b>Francesca Gay</b> , Italy
14:30-15:00	Round table debate <i>Speakers and,</i> <b>Peter Sonneveld</b> , Netherlands <b>Joan Blade</b> , Spain <b>Muzaffar Qazilbash</b> , USA



<b>15:00-16:15</b>	<b>Session 7: Therapy of elderly patients</b>
15:00-15:15	IMiD-based approaches <b>Thierry Facon</b> , France
15:15-15:30	Proteasome-based approaches <b>Marivi Mateos</b> , Spain
15:30-15:45	Personalized treatment of the elderly <b>Sonja Zweegman</b> , Netherlands
15:45-16:15	Round table debate <i>Speakers and,</i> <b>Alessandra Larocca</b> , Italy <b>Meral Beksac</b> , Turkey
<b>16:15-17:45</b>	<b><i>Out of the Trial and into the Real World: Closing the Gap in RRMM Industry Symposium</i></b>
<b>17:45-18:45</b>	<b>Session 8: Therapy of smoldering myeloma – a debate</b>
17:45-18:00	Pro <b>S. Vincent Rajkumar</b> , USA
18:00-18:15	Con <b>Xavier Leleu</b> , France
18:15-18:45	Round table debate <i>Speakers and,</i> <b>Shaji Kumar</b> , USA <b>Aurore Perrot</b> , France <b>Rafat Abonour</b> , USA
<b>18:45-20:00</b>	<b>Session 9: Plenary lectures</b>
18:45-19:10	MRD-based therapy: hope, hype, or reality? <b>Jesus San Miguel</b> , Spain
19:10-19:35	How to extend survival at relapse? <b>Meletios Dimopoulos</b> , Greece
19:35-20:00	Round table debate <i>Speakers and,</i> <b>Jean-Luc Harousseau</b> , France <b>Nizar Bahlis</b> , Canada <b>Kwee Yong</b> , UK <b>Saad Usmani</b> , USA
<b>20:00-21:00</b>	<b><i>Measurable Residual Disease in Multiple Myeloma: A Real-World Experience Perspective Industry Symposium</i></b>



<b>Day 3, Sunday, May 9<sup>th</sup></b>	
<b>09:00-11:00</b>	<b>ORAL PRESENTATIONS</b>
<b>10:00-11:00</b>	<b>Industry symposium timeslot</b>
<b>11:00-12:20</b>	<b>Session 10: Snapshot talks - Practical considerations</b>
11:00-11:10	Practical considerations when using anti-CD38 antibodies <b>Torben Plesner</b> , Denmark
11:10-11:20	Management of cardiovascular adverse events <b>Inger Nijhof</b> , Netherlands
11:20-11:30	MRD monitoring: when, how and in which patient? <b>Bruno Paiva</b> , Spain
11:30-11:40	MGUS diagnosis: a step by step approach <b>Graham Jackson</b> , UK
11:40-11:50	Imaging: the essential work-up <b>Elena Zamagni</b> , Italy
11:50-12:00	COVID-19 vaccination in myeloma <b>Heinz Ludwig</b> , Austria
12:00-12:20	Q&A
<b>12:20-13:30</b>	<b>Industry symposium timeslot</b>
<b>13:30-14:30</b>	<b>Session 11: Bispecific antibodies forum</b>
13:30-13:45	The case for BCMA as a target <b>Alfred Garfall</b> , USA
13:45-14:00	The case for non-BCMA targets <b>Ajai Chari</b> , USA
14:00-14:30	Round table debate <i>Speakers and,</i> <b>Adam Cohen</b> , USA <b>Hermann Einsele</b> , Germany <b>Luciano Costa</b> , USA
<b>14:30-15:30</b>	<b>Session 12: CAR-T cells forum</b>
14:30-14:45	The case for Ide-Cel <b>Noopur Raje</b> , USA
14:45-15:00	The case for Cilta-Cel <b>Deepu Madduri</b> , USA
15:00-15:30	Round table debate <i>Speakers and,</i> <b>Nina Shah</b> , USA <b>Arnon Nagler</b> , Israel <b>Salomon Manier</b> , France <b>Caitlin Costello</b> , USA



<b>15:30-16:30</b>	<b>Session 13: Novel drugs forum</b>
15:30-15:40	Melflufen-based combinations <b>Paul Richardson</b> , USA
15:40-15:50	Iberdomide-based combinations <b>Sagar Lonial</b> , USA
15:50-16:00	XPO inhibitors <b>Mohamad Mohty</b> , France
16:00-16:10	Venetoclax: for which patients? <b>Rafael Fonseca</b> , USA
16:10-16:30	Round table debate moderated by <b>Rafael Fonseca</b> , USA
<b>16:30-17:30</b>	<i><b>Uncharted territories: the expanding RRMM treatment landscape</b></i> <i><b>Industry Symposium</b></i>
<b>17:30-18:00</b>	<b>Session 14: Plenary lecture</b>
17:30-18:00	Multiple myeloma in 2025: the next steps? <b>Kenneth Anderson</b> , USA
<b>18:00-18:30</b>	<b>Awards Ceremony</b>